Clinical Oncology Next-Generation Sequencing Market: Personalized Cancer Care on the Rise in 2024-2031 and Beyond

Clinical Oncology Next Generation Sequencing Market to reach over USD 1.25 Bn by the year 2031 - Exclusive Report by InsightAce Analytic

"Clinical Oncology Next Generation Sequencing Market" in terms of revenue was estimated to be worth $414.28 Mn in 2023 and is poised to reach $1,258.84 Mn by 2031, growing at a CAGR of 15.06% from 2024 to 2031 according to a new report by InsightAce Analytic.

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/2249

Clinical Oncology Next-Generation Sequencing Market: Poised for Growth Despite Challenges

The global clinical oncology next-generation sequencing (NGS) market is experiencing a surge, driven by several key factors:

• Demand for Personalized Medicine: The growing need for targeted therapies and personalized medicine approaches in cancer treatment is a major driver. NGS allows for a deeper understanding of a patient's unique genetic makeup, enabling the selection of the most effective treatments.

• Rising Cancer Rates: The alarming increase in global cancer cases unfortunately fuels the demand for advanced diagnostic tools like NGS.

• Advancements in NGS Technology: Continuous advancements in NGS technology are improving accuracy, efficiency, and affordability, making it a more accessible tool for clinical oncology.
However, the market also faces some challenges:

• Limited Reimbursement: Restrictive reimbursement policies for NGS-based tests can limit their widespread adoption in some healthcare systems.

• Cost Considerations: The high cost of NGS technology and data analysis can be a barrier for some healthcare providers and patients.

• Data Interpretation Hurdles: The lack of standardized protocols for data interpretation and ongoing regulatory hurdles can create uncertainty for clinicians using NGS results for treatment decisions.
Despite these challenges, the future of the clinical oncology NGS market looks promising:

• AI and Machine Learning Integration: The integration of artificial intelligence and machine learning into NGS data analysis has the potential to improve accuracy, efficiency, and overall workflow.

• Expanding Applications: NGS has the potential to be used beyond cancer diagnosis, including applications such as minimal residual disease identification and treatment response monitoring.

• Companion Diagnostics: Collaboration between pharmaceutical companies and NGS service providers can lead to the development of companion diagnostics for targeted therapies, further personalizing cancer treatment.
By overcoming existing hurdles and embracing these growth opportunities, the clinical oncology NGS market is poised to play a vital role in the future of personalized cancer care.

Market Analysis:

Primary factors propelling the growth of the Clinical Oncology Next Generation Sequencing (NGS) market include technological advancements, heightened competition among industry players, escalating healthcare expenditures, and a surge in cancer prevalence. Intensified research and development endeavors aimed at pioneering solutions are anticipated to further drive market expansion. The market has notably been affected by the COVID-19 pandemic, with governmental regulations and guidelines concerning cancer treatment stimulating market activity during this period.

List of Prominent Players in the Clinical Oncology Next Generation Sequencing Market:
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Agilent Technologies Inc. (U.S.)
• Myriad Genetics Inc. (U.S.)
• BGI (China)
• Perkin Elmer Inc. (U.S.)
• Foundation Medicine Inc. (U.S.)
• PacBio (U.S.)
• Oxford Nanopore Technologies plc. (U.K.)
• Paradigm Diagnostics Inc. (U.S.)
• Caris Life Sciences (Japan)
• Partek, Incorporated (U.S.)
• Eurofins Scientific (Luxembourg)
• Qiagen (Germany)

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2249

Recent Developments:

• In January 2022, Agendia, Inc. unveiled a multiyear collaboration with Illumina to jointly create in vitro diagnostic (IVD) assays for oncology testing.

• In October 2021, Roche launched the AVENIO tumor tissue CGP kit to enhance accessibility to personalized cancer research.

Clinical Oncology Next Generation Sequencing Market Dynamics:
Market Drivers: Increasing Acceptance Of Certain Cosmetic Procedures
The rise in cancer incidences, largely influenced by advancements in personalized medicine and oncological treatments, is expected to have a substantial effect on the Clinical Oncology Next Generation Sequencing market.

Factors such as the growing prevalence of cancer, widespread acceptance of sequencing-based diagnostic platforms by oncologists, declining costs of genetic sequencing, and increased government funding for research and development are poised to drive market expansion.

Challenges: High Cost Associated With Dermal Filler Procedures
The significant expense, alongside technological factors, poses a substantial obstacle to the expansion of the Clinical Oncology Next Generation Sequencing market during the forecast period. Elevated expenses associated with acquiring sequencing platforms, inefficiencies in outsourced services, and restricted accessibility of sequencing platforms in certain regional markets are anticipated to impede overall progress.

North America Is Expected To Grow With The Highest CAGR During The Forecast Period:
The North American Clinical Oncology Next-Generation Sequencing Market is likely to register a significant revenue share due to regulatory efforts to enhance cancer screening diagnosis in the U.S., rising investments in research and development, and the significant presence of industry leaders in the area. Key stakeholders in the region are prioritizing technological innovations to fortify their market standing and deliver optimal solutions.

Segmentation of Clinical Oncology Next Generation Sequencing Market-
By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing and Resequencing Centrifuges

By Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

By Application

• Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

By End-user

• Hospitals
• Clinics
• Laboratories

By Region-
North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2249

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.